Dermatology

The FDA approved Dermavant Science's Vtama (tapinarof cream) last year as a treatment for plaque psoriasis. Sales have been disappointing, according to press reports. Will Vtama, which has a different mechanism of action than the current batch of topical medications for atopic dermatitis, fare better in the atopic dermatitis market?

The FDA has set a date of July 07, 2024, for Zorvye 0.15% for adults and children six and up with the chronic skin disease atopic dermatitis.

Vtama is a steroid-free cream that works by targeting the aryl hydrocarbon receptor, which plays a role in regulating immune responses.

The updated guidelines include 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments.

Bimzelx is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

Delgocitinib is first-in-class pan-Janus kinase inhibitor

Data from the study revealed that about half of the patients did not receive any treatment during their 12-month follow-up.

Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.

The FDA is requesting additional efficacy data to support an approval for patients with chronic spontaneous urticaria; results of an ongoing study are expected late next year.

Topline results from week 16 of a phase 3b trial demonstrated the efficacy and safety of Tremfya across all skin tones.

A European study shows that almost 1 in 5 of those with chronic skin conditions felt they were looked at with disgust.

The dosage of Zoryve for children 6 to 11 is the same as for those over the age of 12. The list price is same for both pediatrics and adults — $825 per tube.

The dosage of Zoryve for children 6 to 11 is the same as for those over the age of 12. The list price is same for both pediatrics and adults — $825 per tube.

The similarity of symptoms means children already diagnosed with atopic dermatitis may not receive patch testing for allergic contact dermatitis, resulting in underdiagnosis of the comorbidity, say the authors of a study published in the Journal of the American Academy of Dermatology.

Galderma officials said they have already identified changes to its manufacturing process for relabotulinumtoxinA, which is being reviewed as a treatment for frown lines and crows feet.

In a population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about risks of mortality among these patients. The researchers investigated all-cause and cause-specific mortality of patients with vitiligo compared with controls without vitiligo using a nationwide database.

At issue are findings from the agency’s inspection of a third-party manufacturing company. The FDA indicated there were no concerns about the safety or labeling of lebrikizumab.

The FDA indicated there were no concerns about the safety or labeling of lebrikizumab, which is being reviewed to treat patients with moderate-to-severe atopic dermatitis.

In addition, a supplemental new drug application has been filed for roflumilast cream .15% to treat mild-to-moderate atopic dermatitis in adults and children aged 6 years and older.

Cognitive behavioral therapy with exposure treatment might help but few people with AD receive any form of behavioral intervention, say Dorian Kern and colleagues from Karolinska Institutet, Stockholm.

Patient autonomy needs to be balanced with an obligation to educate patients about the risk and benefits of the complementary and alternative medicine treatments, say the authors of an article in the Journal of the American Academy of Dermatology.

The decision by Scripius (previously Select Health Prescriptions) was made based on the cost of Dupixent, as well as because of an increased demand to use Dupixent for mild atopic dermatitis when the primary patient population is those with moderate to severe disease.

Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.

Scientists say it could lead to new drugs for vitiligo and other pigmentation diseases.

The US accounted for nearly half of the atopic dermatitis drugs market in 2021. According to 2021 data from the National Center for Health Statistics, roughly 7% of adults in the U.S. have eczema.

Mayo Clinic researchers have developed a process that uses human cells as inks, dubbed bioinks, to print natural tissue-like structures in three dimensions.

The study will enroll an estimated 1,000 patients, of whom approximately 200 will have vitiligo. The remaining participants will be at-risk family members, some 40 to 60 of whom are expected to develop vitiligo during the 5-year study.

Ycanth is the first drug to treat children and adults with molluscum contagiosum, a viral skin infection. It will be available in September, but pricing information has not yet been released.

Ycanth, a topical treatment for molluscum contagiosum, will be available in September. Pricing information has not yet been released.

Results reported in JAMA Dermatology today show disagreement between physicians and patients in the grading of skin disease. Physicians tend to see severity relative to other patients, note the researchers, while patients may compare themselves with peers and their social circle.